Antea Participaties

Antea Participaties, established in 1999 and based in The Hague, Netherlands, is a private equity firm focusing on middle market investments. It specializes in growth capital, management buy-outs, and bridge financing, typically investing between €1.5 million and €7.5 million in companies valued between €5 million and €30 million, with an EBITDA of at least €1 million. The firm targets investments in the food, ICT, media, and business services sectors within the Netherlands, taking both minority and majority stakes and aiming for an exit within 5 to 7 years.

Coen Binnerts

Business Analyst

Robert de Boeck

Founder, Director and Managing Partner

Maarten Herreveld

Investment Manager

Roelant Scheepens

Partner

Pieter Wilde RC

Partner and Director

3 past transactions

Fresh Cans

Acquisition in 2019
Fresh Cans, based in Utrecht, Netherlands, offers management consulting services that address modern challenges faced by organizations. The company focuses on employer branding, talent acquisition, and development, as well as strategy and brand activation. By employing young professionals with entrepreneurial spirit, Fresh Cans aims to assist large organizations in transforming, innovating, and accelerating their operations. Through its tailored services, the firm helps clients navigate complex business landscapes and enhance their overall performance.

Uniekaas

Acquisition in 2014
Uniekaas, established in 1965, is a Dutch cheese producer renowned for its high-quality Gouda cheese. With roots tracing back to De KaasUnie, a cooperative of regional cheese traders founded in 1956, Uniekaas operates from its production facility in Kaatsheuvel. The company specializes in producing, maturing, cutting, packaging, and selling cheese products under its own fixed recipes, ensuring no artificial additives or preservatives are used.

to-BBB

Series B in 2011
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.